Immunoglobulins Market: By Product (IgG, IgA, IgM, IgE, and IgD), By Mode of Delivery (Intravenous, and Subcutaneous), By Application (Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy, Immunodeficiency Disease, Myasthenia Gravis, and Others), and Geography

Immunoglobulins Market size was valued at USD 14,782.7 million in 2023 and is poised to grow at a 6.2% CAGR from 2024 to 2030. Immunoglobulins are also referred to as antibodies which a proteins produced by plasma cells and other lymphocytes in the blood. It is a complex entity that exerts its immunomodulatory effect on different components of the immune system. It is obtained from the blood through a fractional process, and it is purified for its therapeutic and non-therapeutic applications. Immunoglobulins are used in the treatment of various immunological and neurological diseases. The increasing geriatric population and growing primary and secondary immunodeficiency diseases are expected to drive the growth of the immunoglobulin market over the forecast period. For instance, according to a research study, there were about 6 million people are affected by primary immunodeficiency diseases across the globe.

In addition, the increasing prevalence of chronic inflammatory demyelinating polyneuropathy, hypogammaglobulinemia, and other Chronic Kidney Disease (CKD) Drugs diseases along with the technological advancement and development of modern purification techniques are expected to boost the growth of immunoglobulins at a significant rate over the forecast period. However, the strict government regulations regarding immunoglobulin products, the side effects caused by it, and high treatment costs are expected to hinder the growth of the immunoglobulin market over the forecast period. For instance, according to an article published in 2020, it illustrated that a patient receives 4 to 5 infusions per month and the average cost of the therapy per month is more than USD 40,000. Moreover, the advancement of technologies, improvement of purification techniques, and increasing approvals of drugs by government-regulated bodies are expected to provide opportunities for the market players in the growth of the immunoglobulins market over the forecast period. For instance, in 2021, the FDA approved Hizentra an immunoglobulin subcutaneous 20% liquid by Behring for the treatment of chronic inflammatory demyelinating polyneuropathy. 

Immunoglobulins Market Key Developments:

• In March 2022, Grifols received approval from several European Union member state health authorities as well as from the United Kingdom for XEMBIFY.